featured
Long-Term Follow-Up of Ocrelizumab for Primary Progressive Multiple Sclerosis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Long-Term Follow-Up From the ORATORIO Trial of Ocrelizumab for Primary Progressive Multiple Sclerosis: A Post-Hoc Analysis From the Ongoing Open-label Extension of the Randomised, Placebo-Controlled, Phase 3 Trial
Lancet Neurol 2020 Dec 01;19(12)998-1009, JS Wolinsky, DL Arnold, B Brochet, HP Hartung, X Montalban, RT Naismith, M Manfrini, J Overell, H Koendgen, A Sauter, I Bennett, S Hubeaux, L Kappos, SL HauserFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.